Investors & Media

2015 Press Releases

Webcast ImageWebcast
Flex Pharma Inc at the Cantor Fitzgerald 2017 Global Healthcare Conference (Live)
09/25/17 at 3:35 p.m. ET
Flex Pharma Inc at the Cantor Fitzgerald 2017 Global Healthcare Conference
Monday, September 25, 2017 3:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/21/15Flex Pharma Added to NASDAQ Biotechnology Index
BOSTON--(BUSINESS WIRE)--Dec. 21, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS): Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for spasms associated with severe neuromuscular conditions, nocturnal leg cramps and exercise-associated muscle cramps, announced today that it has been added to the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effect... 
Printer Friendly Version
12/09/15Flex Pharma Presents at the 26th International Symposium on ALS/MND
-- Study in ALS Patients with FLX-787 Expected to Initiate First Half of 2016 -- BOSTON--(BUSINESS WIRE)--Dec. 9, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for spasms associated with severe neuromuscular conditions, nocturnal leg cramps and exercise-associated muscle cramps, announced today that it will present at the 26th Int... 
Printer Friendly Version
11/23/15Flex Pharma Presenting at Two Upcoming Healthcare Investor Conferences in December 2015
BOSTON--(BUSINESS WIRE)--Nov. 23, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will present a corporate overview at the following upcoming healthcare investor conferences in November: The Piper Jaffray 27th Annual Healthcare Conference on Decemb... 
Printer Friendly Version
11/11/15Flex Pharma Presenting at Two Upcoming Healthcare Investor Conferences in November 2015
BOSTON--(BUSINESS WIRE)--Nov. 11, 2015-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will present a corporate overview at the following upcoming healthcare investor conferences in November: The Stifel Healthcare Conference ... 
Printer Friendly Version
11/10/15Flex Pharma Announces FLX-787 as Clinical Drug Candidate
-- MS, ALS and NLC Studies Expected to Initiate with Single Agent TRP Activator in 2016 -- -- Consumer Product to Prevent and Treat Cramps to Launch in the Second Quarter of 2016 -- BOSTON--(BUSINESS WIRE)--Nov. 10, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS): Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associa... 
Printer Friendly Version
11/04/15Flex Pharma Reports Third Quarter 2015 Financial Results
Conference Call Scheduled Today at 9:00 a.m. ET Click to Tweet this News BOSTON--(BUSINESS WIRE)--Nov. 4, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the quarter ended September 30, 2015, and provided an update on... 
Printer Friendly Version
11/03/15Flex Pharma to Host Investor Day
BOSTON--(BUSINESS WIRE)--Nov. 3, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions, announced that the Company is hosting an Investor Day on Tuesday, November 10, 2015 in New York from 2:00-4:00pm ET. The event wi... 
Printer Friendly Version
10/28/15Flex Pharma to Report Third Quarter 2015 Results on November 4, 2015
BOSTON--(BUSINESS WIRE)--Oct. 28, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the quarter ended September 30, 2015 on Wednesday, November 4, 201... 
Printer Friendly Version
10/20/15Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps
-- Presentation at the Society for Neuroscience -- BOSTON--(BUSINESS WIRE)--Oct. 20, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today that it will present data demonstrating GMP-synthesized single agent ef... 
Printer Friendly Version
10/13/15Flex Pharma Co-Founder and Harvard Medical School Professor Bruce Bean to Speak about Chemical Neuro Stimulation at Neuro Advance Boston
BOSTON--(BUSINESS WIRE)--Oct. 13, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced that Chief Medical Officer, Dr. Tom Wessel, will lead a panel of thought leaders including National Academy of Sciences member Dr. B... 
Printer Friendly Version
10/07/15Flex Pharma Partners with Five Time World Champion Triathlete Craig “Crowie” Alexander
KONA, Hawaii--(BUSINESS WIRE)--Oct. 7, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a company developing innovative and proprietary treatments for exercise-associated muscle cramps, has signed an exclusive partnership with World Champion triathlete Craig “Crowie” Alexander from Australia around its scientific breakthrough to prevent and treat muscle cramps. Alexander is a three-time IRONMAN® World Champion and t... 
Printer Friendly Version
10/06/15Flex Pharma Demonstrates Efficacy of Synthesized Single and Combination Agents in Reducing Human Muscle Cramps
-- Presentation at the European Committee for Treatment and Research of Multiple Sclerosis -- BOSTON--(BUSINESS WIRE)--Oct. 6, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today that it will present data ... 
Printer Friendly Version
09/22/15Flex Pharma to Present at the Ladenburg Thalmann Investment Conference
BOSTON--(BUSINESS WIRE)--Sep. 22, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Company management will present a corporate overview at the Ladenburg Thalmann 2015 Healthcare Conference, on September 29, 2015 at 9:30 a.m. ET in N... 
Printer Friendly Version
09/21/15Flex Pharma Educates Athletes about Breakthrough Discovery
BOSTON--(BUSINESS WIRE)--Sep. 21, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, has launched a print and digital campaign with the objective to build awareness and educate consumers that the root cause of muscle cramping is the nerve, n... 
Printer Friendly Version
09/09/15Flex Pharma Appoints Kathie Lindemann Chief Operating Officer
-Former DAVIDs TEA COO & Starbucks SVP International Operations- BOSTON--(BUSINESS WIRE)--Sep. 9, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced the appointment of Kathie Lindemann as its Chi... 
Printer Friendly Version
09/08/15Rob Perez Joins Flex Pharma’s Board of Directors
-Former Cubist CEO- BOSTON--(BUSINESS WIRE)--Sep. 8, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Robert J. Perez, former Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joine... 
Printer Friendly Version
09/02/15Flex Pharma to Present at the Rodman & Renshaw Investment Conference
BOSTON--(BUSINESS WIRE)--Sep. 2, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Company management will present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference, on September 9, 2015 at 11:... 
Printer Friendly Version
08/05/15Flex Pharma Reports Second Quarter 2015 Financial Results
Conference Call Scheduled Today at 9:00 a.m. ET BOSTON--(BUSINESS WIRE)--Aug. 5, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the quarter ended June 30, 2015, and provided ... 
Printer Friendly Version
07/29/15Flex Pharma to Report Second Quarter 2015 Results on August 5, 2015
BOSTON--(BUSINESS WIRE)--Jul. 29, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the quarter ended June 30, 2015 on Wednesday, August 5, 2015 befor... 
Printer Friendly Version
07/28/15Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings
Abstracts accepted at the European Committee for Treatment and Research of Multiple Sclerosis and the Society for Neuroscience BOSTON--(BUSINESS WIRE)--Jul. 28, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, tod... 
Printer Friendly Version
07/07/15Flex Pharma Announces Reduction of Muscle Cramping in Athletes
-- Significant Effect in Preventing Exercise-Associated Muscle Cramps -- BOSTON--(BUSINESS WIRE)--Jul. 7, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced its proprietary treatment pr... 
Printer Friendly Version
07/01/15Flex Pharma to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
BOSTON--(BUSINESS WIRE)--Jul. 1, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Company management will present a corporate overview at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8, 2015 at 11:45am ET... 
Printer Friendly Version
06/15/15Alfred Sandrock, Jr., M.D., Ph.D., Chief Medical Officer of Biogen, Joins Flex Pharma’s Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--Jun. 15, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Alfred Sandrock, Jr., M.D., Ph.D., Chief Medical Officer of Biogen (NASDAQ: BIIB), has joined its Scientif... 
Printer Friendly Version
06/02/15Flex Pharma Presenting at Two Upcoming Consumer Investor Conferences in June 2015
BOSTON--(BUSINESS WIRE)--Jun. 2, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a company that is developing innovative and proprietary treatments for exercise-associated muscle cramps and nocturnal leg cramps, today announced that it will present a corporate overview at the following upcoming consumer investor conferences in June: The Piper Jaffray 35th Annual Consumer Conference on June 9, 2015... 
Printer Friendly Version
06/01/15Flex Pharma to Ring the NASDAQ Stock Market Closing Bell
BOSTON--(BUSINESS WIRE)--Jun. 1, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Nobel Laureate and Scientific Co-Founder, Rod MacKinnon, M.D., and Chief Executive Officer, Christoph Westphal, M.... 
Printer Friendly Version
05/28/15Flex Pharma Presenting at Two Upcoming Healthcare Investor Conferences in June 2015
BOSTON--(BUSINESS WIRE)--May 28, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS): Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will present a corporate overview at the following upcoming healthcare investor conferences in June: ... 
Printer Friendly Version
05/06/15Flex Pharma Reports First Quarter 2015 Financial Results
Conference Call Scheduled Today at 9:00 a.m. ET BOSTON--(BUSINESS WIRE)--May 6, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the quarter ended March 31, 2015, and provided ... 
Printer Friendly Version
05/04/15NSF Approves Flex Pharma’s Proprietary Formulation under NSF’s Certified for Sport® Program
BOSTON--(BUSINESS WIRE)--May 4, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that its proprietary formulation has earned certification from NSF International's Certified for Sport® program. Flex Ph... 
Printer Friendly Version
04/29/15Flex Pharma to Report First Quarter 2015 Results on May 6, 2015
BOSTON--(BUSINESS WIRE)--Apr. 29, 2015-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the quarter ended March 31, 2015 on Wednesday, May 6, 2015 before the U.S. f... 
Printer Friendly Version
04/27/15Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps
BOSTON--(BUSINESS WIRE)--Apr. 27, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that it has initiated a human proof-of-concept efficacy study in nocturnal leg cramps (NLC) with its proprietar... 
Printer Friendly Version
04/21/15Flex Pharma Data Presented at AAN Platform Session
Company Presents Human Proof-of-Concept for Treating and Preventing Muscle Cramps BOSTON--(BUSINESS WIRE)--Apr. 21, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Flex Pharma Scientif... 
Printer Friendly Version
04/13/15John Winkelman, M.D., Ph.D., Joins Flex Pharma’s Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--Apr. 13, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that John Winkelman, M.D., Ph.D., Chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hosp... 
Printer Friendly Version
04/06/15Jeffrey D. Capello Appointed to Flex Pharma’s Board of Directors
BOSTON--(BUSINESS WIRE)--Apr. 6, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Jeffrey D. Capello, Chief Financial Officer of Ortho-Clinical Diagnostics, Inc., has joined its Board of Directors... 
Printer Friendly Version
04/01/15Flex Pharma Added to Russell 3000®, Russell 2000®, and Russell Microcap® Indices
BOSTON--(BUSINESS WIRE)--Apr. 1, 2015-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that it has been added to the Russell 3000, Russell 2000, and Russell Microcap Indices as part of Russell Investments' first quar... 
Printer Friendly Version
03/17/15Flex Pharma Reports Year End 2014 Financial Results
Conference Call Scheduled Today at 9:00 a.m. ET BOSTON--(BUSINESS WIRE)--Mar. 17, 2015-- (Click to Tweet) -- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the year ended December 31, 2014 and provided an update on its clinical ... 
Printer Friendly Version
03/16/15Thomas Wessel, M.D., Ph.D., Appointed Chief Medical Officer
Elizabeth Woo Promoted to SVP BOSTON--(BUSINESS WIRE)--Mar. 16, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced the appointment of Thomas Wessel, M.D., Ph.D., as its Chief Medical Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pha... 
Printer Friendly Version
03/10/15Flex Pharma to Report Full Year 2014 Results on March 17, 2015
BOSTON--(BUSINESS WIRE)--Mar. 10, 2015-- Flex Pharma, Inc. (NASDAQ:FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the year ended December 31, 2014 on Tuesday, March 17, 2015 before the U.S. financial markets open. The Company will host a conference call and webcast at ... 
Printer Friendly Version
03/09/15Flex Pharma Announces Establishment of Stock Purchase Plan by Chief Executive Officer
BOSTON--(BUSINESS WIRE)--Mar. 9, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D., has established a pre-arranged personal stock purchasing plan to acquire shares of the ... 
Printer Friendly Version
03/03/15Medtronic, Leading Neurostimulation Company, Invests in Flex Pharma IPO
BOSTON--(BUSINESS WIRE)--Mar. 3, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Medtronic invested in the Flex Pharma initial public offering on January 29, 2015. "As a market leader in neurostimulation to ameliorate a wide range of ... 
Printer Friendly Version
02/26/15Flex Pharma Presenting at Three Upcoming Investor Conferences in March 2015
BOSTON--(BUSINESS WIRE)--Feb. 26, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will present a corporate overview at the following upcoming investor conferences in March: The 35th Annual Cowen and Company Healthcare Conference on March 4, 2015 at... 
Printer Friendly Version
02/24/15Nobel Laureate, Rod MacKinnon, M.D., Joins Flex Pharma’s Board of Directors
BOSTON--(BUSINESS WIRE)--Feb. 24, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Nobel Laureate and Scientific Co-Founder, Rod MacKinnon, M.D., has joined its Board of Directors. In addition, Scientific Co-Founder, Bruce Bean, Ph.D., will ... 
Printer Friendly Version
02/18/15AAN Selects Flex Pharma Data for Oral Platform Presentation
Company to Present Human Proof-of-Concept for Treating and Preventing Muscle Cramps BOSTON--(BUSINESS WIRE)--Feb. 18, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that the Company’s data have been selected for an oral platform p... 
Printer Friendly Version
02/11/15Flex Pharma CEO Christoph Westphal, M.D., Ph.D., Joins BIO Emerging Companies Governing Board
BOSTON--(BUSINESS WIRE)--Feb. 11, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Flex Pharma Co-founder and CEO, Christoph Westphal, M.D., Ph.D., has been appointed to the Biotechnology Industry Organization (BIO) Emerging Companies ... 
Printer Friendly Version
02/04/15Flex Pharma Announces Closing Of Initial Public Offering
BOSTON--(BUSINESS WIRE)--Feb. 4, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds of $86.4 million, before underwriting di... 
Printer Friendly Version
01/28/15Flex Pharma Announces Pricing Of Initial Public Offering
Boston, MA – Flex Pharma, Inc., a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Flex Pharma. In addition, the company has granted the underw... 
Printer Friendly Version